This information is intended for US healthcare professionals.

EPCLUSA is indicated for the treatment of adults with chronic hepatitis C virus (HCV) GT 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.

TEST AND CONNECT TO CARE.

HEPATITIS C
IS A CURABLE
LIFE-THREATENING
DISEASE1,2

TEST AND CONNECT TO CARE.

HEPATITIS C
IS A CURABLE
LIFE-THREATENING
DISEASE1,2

Learn how cure starts with you

Steps can be taken in your practice to identify patients who need treatment and help connect them to a cure1

MANY PATIENTS
AREN'T AWARE THEY
NEED TREATMENT3

Among 2.7 million infected HCV patients, 24 percent have been diagnosed and in 2018, 5 percent were treated
10 percent to 20 percent risk of cirrhosis with hepatitis C

UNTREATED HCV CAN LEAD
TO LIFE-THREATENING
COMPLICATIONS4

and can cause serious
complications beyond
the liver5

Baby Boomers born 1945-1965 represent 57 percent of HCV infections
People who have injected drugs account for almost 80 percent of new HCV infections in 2014

SCREEN EVERY AT-RISK PATIENT, REGARDLESS
OF SYMPTOMS1,4

AASLD/IDSA and CDC recommended

Screen with an HCV antibody test.1

CONFIRM DIAGNOSIS
WITH AN HCV RNA TEST1,4

Select “reflex testing” at laboratory screening to automatically test for HCV RNA with a positive HCV antibody result.1

Diagnosis and screening for hepatitis C

CURE IS POSSIBLE FOR
MOST PATIENTS WITH HCV1,2

REFER FOR TREATMENT

  • Educate patients on the importance of prompt treatment
  • Find a healthcare provider who has experience treating HCV infection and is located near your patient

AMA doctor finder

Follow up to ensure patients receive treatment for hepatitis C
Follow up to ensure your patient has received treatment
OR

TREAT IN YOUR PRACTICE

Treating in your practice can help ensure that your patients receive prompt care.

Many HCV patients do not follow up with treatment

▲ Back to top

a AASLD/IDSA does not recommend treatment in patients with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. Patients with a short life expectancy owing to liver disease should be managed in consultation with an expert.

AASLD/IDSA = American Association for the Study of Liver Diseases/Infectious Diseases Society of America; CDC = Centers for Disease Control and Prevention; CYP = cytochrome P450; GT = genotype; P-gp = P-glycoprotein; USPSTF = United States Preventive Services Task Force; WHO = World Health Organization.

AASLD/IDSA = American Association for the Study of Liver Diseases/Infectious Diseases Society of America; CDC = Centers for Disease Control and Prevention; CYP = cytochrome P450; GT = genotype; P-gp = P-glycoprotein; USPSTF = United States Preventive Services Task Force; WHO = World Health Organization.

REFERENCES:
  1. AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed July 12, 2019.
  2. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. License: CC BY-NC-SA 3.0 IGO.
  3. Data on file. Chhatwal email. April 25, 2019.
  4. Hepatitis C questions and answers for health professionals. Centers for Disease Control and Prevention website. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed July 12, 2019.
  5. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3-14.
  6. Chhatwal J, Chen Q, Bethea ED, et al. Changing cascade of care for hepatitis C in the era of direct-acting antivirals. Presented at: AASLD: The Liver Meeting®; November 9-13, 2018; San Francisco, CA.
  7. Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-181.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Contraindications

  • If EPCLUSA is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

  • Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with EPCLUSA due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir-containing regimen. In patients without alternative viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of EPCLUSA with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with EPCLUSA as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

  • The most common adverse reactions (10%, all grades) with EPCLUSA were headache and fatigue; and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Drug Interactions

  • Coadministration of EPCLUSA is not recommended with topotecan due to increased concentrations of topotecan.
  • Coadministration of EPCLUSA is not recommended with proton-pump inhibitors, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.

Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences, as regulatory control, legal requirements, and/or medical practices may vary in other countries.



Photos not of actual patients.

EPCLUSA, the EPCLUSA logo, SUPPORT PATH, GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.

©2019 Gilead Sciences, Inc. All rights reserved. EPCP0419 08/19